We are live on ! Find out more
NHAS

Novo Holdings A/S Portfolio holdings

AUM $1.23B
1-Year Est. Return 81.32%
This Fund
S&P 500
This Quarter Est. Return
+4.22%
1 Year Est. Return
+81.32%
3 Year Est. Return
+192.63%
5 Year Est. Return
+125.03%
10 Year Est. Return
+943.65%
AUM
$1.18B
AUM Growth
-$60.4M
Cap. Flow
-$129M
Cap. Flow %
-10.94%
Top 10 Hldgs %
96.84%
Holding
15
New
–
Increased
1
Reduced
2
Closed
1

Top Buys

Rank Stock Value
1
ELDN icon
Eledon Pharmaceuticals
ELDN
+$70.6K

Top Sells

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$51.5M
2
TTPH
Tetraphase Pharmaceuticals, Inc.
TTPH
+$46.7M
3
XENT
Intersect ENT, Inc
XENT
+$8M

Sector Composition

Rank Sector Weight
1 Healthcare 59.57%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VTI icon
1
Vanguard Total Stock Market ETF
VTI
$655B
$320M 27.18%
2,979,100
– –
ISEE
2
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$228M 19.43%
4,910,487
-991,332
-17% -$51.5M
VGK icon
3
Vanguard FTSE Europe ETF
VGK
$30.1B
$114M 9.69%
2,101,000
– –
INGN icon
4
Inogen
INGN
$171M
$114M 9.66%
3,549,320
– –
NVRO
5
DELISTED
NEVRO CORP.
NVRO
$105M 8.95%
2,194,841
– –
ALDR
6
DELISTED
Alder Biopharmaceuticals
ALDR
$92.4M 7.86%
3,201,183
– –
OTIC
7
DELISTED
Otonomy, Inc.
OTIC
$76.9M 6.54%
2,175,025
– –
FLXN
8
DELISTED
Flexion Therapeutics, Inc.
FLXN
$51.4M 4.37%
2,283,131
– –
AKBA icon
9
Akebia Therapeutics
AKBA
$343M
$16.8M 1.43%
1,516,387
– –
ELDN icon
10
Eledon Pharmaceuticals
ELDN
$276M
$13.4M 1.14%
7,310
+32
+0.4% +$70.6K
AERI
11
DELISTED
Aerie Pharmaceuticals
AERI
$13.2M 1.12%
419,652
– –
TTPH
12
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$8.48M 0.72%
11,571
-62,179
-84% -$46.7M
XENE icon
13
Xenon Pharmaceuticals
XENE
$6.36B
$2.15M 0.18%
127,563
– –
XENT
14
DELISTED
Intersect ENT, Inc
XENT
– –
-350,000
Closed -$8M

Similar funds

HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
CA
Cullinan Associates Louisville, Kentucky $1.24B AUM 28.12% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
WTA
Washington Trust Advisors Wellesley, Massachusetts $1.24B AUM 22.58% 1-Year Est. Return
CCA
Clearwater Capital Advisors Hoffman Estates, Illinois $1.24B AUM 15.23% 1-Year Est. Return

Novo Holdings A/S's Q1 2015 Portfolio in Review

As of Q1 2015, Novo Holdings A/S held 15 positions worth $1.18B, down 4.9% from $1.24B the previous quarter. Its ten largest holdings account for 97% of the portfolio.

Novo Holdings A/S withdrew a net $129M in Q1 2015, closing 1 position and reducing 2 holdings. Its most notable exit was Intersect ENT, Inc, an estimated $8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 60% of assets, up from 57% a quarter earlier.

Against the trend, Novo Holdings A/S added an estimated $70.6K to Eledon Pharmaceuticals.

  • Novo Holdings A/S added most to Eledon Pharmaceuticals in Q1 2015, an estimated $70.6K increase.
  • Novo Holdings A/S's biggest Q1 2015 reduction was IVERIC bio, Inc. Common Stock, cutting an estimated $51.5M.
  • Novo Holdings A/S fully exited Intersect ENT, Inc in Q1 2015, selling an estimated $8M.
  • Novo Holdings A/S's ten largest holdings make up 97% of its $1.18B portfolio in Q1 2015.
  • Novo Holdings A/S opened 0 new positions and closed 1 in Q1 2015.
  • Novo Holdings A/S's portfolio value fell 4.9% quarter-over-quarter to $1.18B.

Based on Novo Holdings A/S's 13F filing for Q1 2015, filed 15 May 2015.